Haemostatix is developing first-in-class clotting agents for the treatment of bleeding or ‘haemostasis’. The company has pioneered a new approach to the control of bleeding that is based on a peptide that binds to the clotting protein fibrinogen, inducing the rapid and targeted formation of clots. This innovative technology platform is being used to develop a pipeline of topical and systemic products to prevent or control different forms of bleeding.

Haemostatix's products include:  PeproStat, a topical haemostat that can be applied as a spray during surgery and is designed to control bleeding and seal incisions or wounds. PeproStat has a novel mode of action that is faster than thrombin-mediated clotting, resulting in improved efficacy.  HaemoPlax™, a platelet substitute in development for the prevention of bleeding in leukaemic patients with platelet deficiency or ‘thrombocytopenia'. HXTC901 is a 'pro-drug' version of HaemoPlax that is activated by the enzyme thrombin at a wound site. HXTC 901 is designed to control more active bleeds in surgery or trauma. 

Haemostatix is based at BioCity, Nottingham, United Kingdom. More...